Research Paper Volume 13, Issue 24 pp 25799—25845

Figure 1. Comparison of mRNA and protein expression of ARHGAP30 in lung cancer tissues and normal tissues. (A) Summary view of ARHGAP30. The transcription level of ARHGAP30 in different types of cancer. P-value < 0.05, Note: The Z-score standardizes the color to describe the relative value in the row. Among them, red indicates overexpression or copy acquisition of genes in the analysis; blue indicates low expression or copy loss of genes in these analyses. Datasets comprised samples represented as microarray data measuring mRNA expression in primary tumors, cell lines, or xenografts. (B) Transcription of ARHGAP30 in lung adenocarcinoma (from Oncomine, SurvExpress, and GEPIA databases). mRNA expression levels of ARHGAP30 were significantly higher in lung adenocarcinoma than in normal tissue. (B1–B3) The fold change, associated p-values, and overexpression Gene Rank, based on Oncomine 4.5 analysis. Box plots show ARHGAP30 mRNA levels in the Hou Lung, Selamat Lung, and Okayama Lung datasets. (B4, B5) The expression of ARHGAP30 in LUAD based on SurvExpress analysis; (B6) The expression of ARHGAP30 in LUAD based on GEPIA analysis; P values as described in the figure are statistically significant. (C) ARHGAP30 transcription in subgroups of patients with lung adenocarcinoma, stratified based on sex, age, and other criteria (UALCAN). (C1) Sample types. (C2) Individual cancer stages. (C3) Ethnicity. (C4) Sex. (C5) Age. (C6) Smoking habits. (C7) Nodal metastasis status. (C8) TP53 mutation status. ☆, P < 0.05; ☆☆, P < 0.01; ☆☆☆, P < 0.001. (D) Differential abundance of the ARHGAP30 protein in patients with lung adenocarcinoma, stratified by sex, age, and other criteria. (D1) Sample types. (D2) Individual cancer stages. (D3) Ethnicity. (D4) Sex. (D5) Age. (D6) Weight. (D7) Tumor grade. (D8) Tumor histology. ☆, P < 0.05; ☆☆, P < 0.01; ☆☆☆, P < 0.001.